B组链球菌母体疫苗的免疫原性与安全性:一项系统综述
该系统综述检索截至2023年7月的文献,纳入20项研究和6项子研究,涉及4440名非妊娠参与者和1325名孕妇及其新生儿。结果显示,与安慰剂组相比,接种疫苗组IgG几何平均浓度和胎盘转移率显著更高,峰值反应在接种后4-8周出现,且未观察到与疫苗接种直接相关的特别关注的不良事件。
要点
- 接种疫苗组IgG几何平均浓度和胎盘转移率显著高于安慰剂组,峰值反应在接种后4-8周。
- 五项研究中的胎盘转移率范围为0.4至1.4。
- 疫苗组与安慰剂组在严重不良事件、导致退出的严重不良事件及全身性疾病或发热风险上无显著差异。
核心结论
- 已发表的临床试验显示,与安慰剂相比,接受结合荚膜多糖疫苗和表面亚单位蛋白疫苗的受试者IgG几何平均浓度反应显著。
- 在当前实验性B组链球菌母体疫苗的临床试验中,未观察到与疫苗接种直接相关的特别关注的不良事件。
研究设计与样本
- 系统综述,检索EMBASE、MEDLINE、Cochrane图书馆和clinicaltrial.gov数据库,纳入1996年1月1日至2023年7月31日间报告非妊娠成人、孕妇和婴儿B组链球菌疫苗免疫原性和/或安全性的临床研究。
- 共纳入20项研究和6项子研究,涉及4440名非妊娠参与者和1325名孕妇及其新生儿。
主要发现
- 接种疫苗组IgG几何平均浓度和IgG胎盘转移率显著高于安慰剂组,峰值反应在接种后4-8周。
- 五项研究中的胎盘转移率范围为0.4至1.4。
- 不同临床试验使用了不同的检测方法,限制了直接比较。
- 疫苗组与安慰剂组在严重不良事件风险(调整OR 0.73;95%CI 0.49-1.07)、导致退出的严重不良事件风险(调整OR 0.44;95%CI 0.13-1.51)以及全身性疾病或发热风险(调整OR 1.05;95%CI 0.26-4.19)方面无显著差异。
局限性
- 不同临床试验使用了不同的检测方法,限制了直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically review immunogenicity and safety data of maternal group B streptococcal (GBS) vaccines in published clinical trials until July 2023. METHODS: EMBASE, MEDLINE, Cochrane Library and clinicaltrial.gov. databases were searched for clinical studies that reported immunogenicity and/or safety of GBS vaccine in non-pregnant adults, pregnant women and infants between 1st of January 1996 to 31st of July 2023. Pairs of reviewers independently selected, data extracted, and assessed the risk of bias of the studies. Discrepancies were resolved by consensus. (PROSPERO CRD42020185213). RESULTS: We retrieved 1472 records from the literature search; 20 studies and 6 sub-studies were included, involving 4440 non-pregnant participants and 1325 pregnant women with their newborns. There was a significantly higher IgG Geometric Mean Concentration (GMC) and IgG placental transfer ratios in vaccinated compared to placebo groups, with peak response 4-8 weeks after vaccination. Placental transfer ratio varied from 0.4 to 1.4 across five studies. The different clinical trials used different assays that limited direct comparison. There were no significant differences in the risk of serious adverse events (adjusted OR 0.73; 95 % CI 0.49-1.07), serious adverse events leading to withdrawal (adjusted OR 0.44; 95 % CI 0.13-1.51), and systemic illness or fever (adjusted OR 1.05; 95 % CI 0.26-4.19) between the vaccine and placebo groups. CONCLUSIONS: The published clinical trials show significant IgG GMC response in subjects receiving the conjugated capsular polysaccharide and surface subunit protein vaccines compared to placebo. In current clinical trials of experimental GBS maternal vaccines, there have been no observed serious adverse events of special interest directly linked to vaccination.
引用
- Bjerkhaug AU, Ramalingham S, Mboizi R, et al. The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review. Vaccine. 2023. PMID: 38072754. doi:10.1016/j.vaccine.2023.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。